<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079404</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01811</org_study_id>
    <secondary_id>ADVL0316</secondary_id>
    <secondary_id>CDR0000355714</secondary_id>
    <secondary_id>COG-ADVL0316</secondary_id>
    <secondary_id>U01CA097452</secondary_id>
    <nct_id>NCT00079404</nct_id>
  </id_info>
  <brief_title>17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia</brief_title>
  <official_title>A Phase I Study of 17-AAG in Relapsed/Refractory Pediatric Patients With Solid Tumors or Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of&#xD;
      17-N-allylamino-17-demethoxygeldanamycin in treating young patients with relapsed or&#xD;
      refractory solid tumors or leukemia. Drugs used in chemotherapy, such as&#xD;
      17-N-allylamino-17-demethoxygeldanamycin, work in different ways to stop cancer cells from&#xD;
      dividing so they stop growing or die.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the maximum tolerated dose (MTD) and recommended phase II dose of 17-AAG&#xD;
      administered as a 60 or 120-minute intravenous infusion on days 1, 4, 8, and 11, of a 21-day&#xD;
      course, to children with refractory solid tumors or relapsed leukemia.&#xD;
&#xD;
      II. To define and describe the toxicities of 17-AAG administered on this schedule.&#xD;
&#xD;
      III. To characterize the pharmacokinetics of 17-AAG in children with refractory cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To preliminarily define the antitumor activity of 17-AAG within the confines of a phase I&#xD;
      study.&#xD;
&#xD;
      II. To assess the biologic activity of 17-AAG. III. To examine the role of CYP3A5&#xD;
      polymorphisms in the pharmacologic and clinical phenotypes observed following administration&#xD;
      of 17-AAG to children, within the confines of a phase 1 study.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study.&#xD;
&#xD;
      Patients with solid tumors receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over&#xD;
      60-120 minutes on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 17 courses&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of 17-AAG until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients&#xD;
      experience dose-limiting toxicity. Once the MTD is determined, up to 6 additional patients&#xD;
      with leukemia receive 17-AAG at the MTD as above. If these 6 patients tolerate this regimen,&#xD;
      another 6 leukemia patients receive 17-AAG IV over 60 minutes on days 1, 4, 8, 11, 15, and&#xD;
      18.&#xD;
&#xD;
      Treatment repeats every 28 days for 17 courses in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients are followed at 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD defined as the maximum dose at which fewer than one-third of patients experience DLT</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Acute Undifferentiated Leukemia</condition>
  <condition>Recurrent Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Childhood Acute Myeloid Leukemia</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with solid tumors receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 60-120 minutes on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tanespimycin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>17-AAG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of solid tumor or leukemia with documented M3&#xD;
             marrow&#xD;
&#xD;
               -  Histologic confirmation of intrinsic brain stem tumors not required&#xD;
&#xD;
          -  Relapsed or refractory disease&#xD;
&#xD;
          -  No known curative therapy&#xD;
&#xD;
          -  In patients with CNS tumors, neurologic deficits must be stable for at least the past&#xD;
             week&#xD;
&#xD;
          -  Performance status - Karnofsky 50-100% (&gt;10 years of age)&#xD;
&#xD;
          -  Performance status - Lansky 50-100% (≤ 10 years of age)&#xD;
&#xD;
          -  For patients with solid tumors:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm^3 (transfusion independent)&#xD;
&#xD;
               -  Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions)&#xD;
&#xD;
          -  For patients with leukemia:&#xD;
&#xD;
               -  Platelet count ≥ 20,000/mm^3 (may receive platelet transfusions)&#xD;
&#xD;
               -  Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Albumin ≥ 2 g/dL&#xD;
&#xD;
          -  Creatinine clearance OR radioisotope glomerular filtration rate ≥ 70 mL/min&#xD;
&#xD;
          -  Creatinine based on age as follows:&#xD;
&#xD;
               -  ≤ 0.8 mg/dL if ≤ 5 years of age&#xD;
&#xD;
               -  ≤ 1.0 mg/dL if &gt; 5 years and ≤ 10 years of age&#xD;
&#xD;
               -  ≤ 1.2 mg/dL if &gt; 10 years and ≤ 15 years of age&#xD;
&#xD;
               -  ≤ 1.5 mg/dL if &gt; 15 years and ≤ 21 years of age&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No prior severe allergy to eggs&#xD;
&#xD;
          -  No situation that would preclude study participation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  At least 7 days (or window for adverse effects has passed) since prior biologic&#xD;
             therapy and recovered&#xD;
&#xD;
          -  At least 7 days since prior hematopoietic growth factors&#xD;
&#xD;
          -  At least 2 months since prior stem cell transplantation and no evidence of&#xD;
             graft-vs-host disease&#xD;
&#xD;
          -  No concurrent hematopoietic growth factors&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)&#xD;
             and recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent steroid therapy&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative radiotherapy (small port)&#xD;
&#xD;
          -  At least 3 months since prior total body irradiation or craniospinal radiotherapy&#xD;
&#xD;
          -  At least 3 months since prior radiotherapy to ≥ 50% of the pelvis&#xD;
&#xD;
          -  At least 6 weeks since prior substantial bone marrow radiotherapy&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
&#xD;
          -  No concurrent phenytoin or phenobarbital&#xD;
&#xD;
          -  No concurrent warfarin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenda Weigel</last_name>
    <role>Principal Investigator</role>
    <affiliation>COG Phase I Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>COG Phase I Consortium</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>March 8, 2004</study_first_submitted>
  <study_first_submitted_qc>March 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2004</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

